{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:13:30Z","timestamp":1762254810111},"reference-count":31,"publisher":"Pan African Medical Journal","content-domain":{"domain":["panafrican-med-journal.com"],"crossmark-restriction":true},"short-container-title":["Pan Afr Med J"],"DOI":"10.11604\/pamj.2024.47.111.40405","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T07:00:08Z","timestamp":1709794808000},"update-policy":"http:\/\/dx.doi.org\/10.11604\/pamj.2016.07.30.0001","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiological, clinical and therapeutic profiles of mantle cell lymphoma cared for in a Moroccan center: a review of 14 cases"],"prefix":"10.11604","volume":"47","author":[{"given":"Ouadii","family":"Abakarim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adil","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelaziz","family":"Hebbezni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imane","family":"Boujguenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima Ezzahra","family":"Lahlimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Illias","family":"Tazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4870","published-online":{"date-parts":[[2024]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3109\/10428190903288514","article-title":"Mantle cell lymphoma: state-of-the-art management and future perspective","volume":"50","author":"Weigert O Unterhalt M Hiddemann W Dreyling M","year":"2009","unstructured":"1. Weigert O Unterhalt M Hiddemann W Dreyling M Mantle cell lymphoma: state-of-the-art management and future perspective Leuk Lymphoma 2009 Dec5012 193750","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"ref2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH Campo E Pileri SA Harris NL Stein H Siebert et al","year":"2016","unstructured":"2. Swerdlow SH Campo E Pileri SA Harris NL Stein H Siebert et al The 2016 revision of the World Health Organization classification of lymphoid neoplasms Blood 2016 May 1912720 237590","journal-title":"Blood"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez V Salamero O Espinet B Sol\u00e9 F Royo C Navarro A et al","year":"2010","unstructured":"3. Fern\u00e0ndez V Salamero O Espinet B Sol\u00e9 F Royo C Navarro A et al Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma Cancer Res 2010 Feb 15704 140818","journal-title":"Cancer Res"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network","volume":"131","author":"Tiemann M Schrader C Klapper W Dreyling MH Campo E Norton A et al","year":"2005","unstructured":"4. Tiemann M Schrader C Klapper W Dreyling MH Campo E Norton A et al Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network Br J Haematol 2005 Oct1311 2938","journal-title":"Br J Haematol"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma","volume":"111","author":"Hoster E Dreyling M Klapper W Gisselbrecht C van Hoof A Kluin-Nelemans HC et al","year":"2008","unstructured":"5. Hoster E Dreyling M Klapper W Gisselbrecht C van Hoof A Kluin-Nelemans HC et al A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma Blood 2008 Jan 151112 55865","journal-title":"Blood"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","article-title":"Mantle cell lymphoma: a retrospective study of 121 cases","volume":"12","author":"Samaha H Dumontet C Ketterer N Moullet I Thieblemont C Bouafia et al","year":"1998","unstructured":"6. Samaha H Dumontet C Ketterer N Moullet I Thieblemont C Bouafia et al Mantle cell lymphoma: a retrospective study of 121 cases Leukemia 1998 Aug128 12817","journal-title":"Leukemia"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini M Zucca E","year":"2009","unstructured":"7. Ghielmini M Zucca E How I treat mantle cell lymphoma Blood 2009 Aug 201148 146976","journal-title":"Blood"},{"issue":"7877","key":"ref8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0140-6736(74)91786-3","article-title":"Classification of non-Hodgkin's lymphomas [letter]","volume":"304","author":"Bennett M Farrer-Brown G Henry K Jelliffe AM Gerard-Marchant R Hamlin I et al","year":"1974","unstructured":"8. Bennett M Farrer-Brown G Henry K Jelliffe AM Gerard-Marchant R Hamlin I et al Classification of non-Hodgkin's lymphomas [letter] Lancet 1974 Aug 173047877 4058","journal-title":"Lancet"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","author":"Ondrejka SL Lai R Smith SD Hsi ED","year":"2011","unstructured":"9. Ondrejka SL Lai R Smith SD Hsi ED Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis Haematologica 2011 Aug968 11217","journal-title":"Haematologica"},{"issue":"20","key":"ref10","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro A Clot G Royo C Jares P Hadzidimitriou A Agathangelidis A et al","year":"2012","unstructured":"10. Navarro A Clot G Royo C Jares P Hadzidimitriou A Agathangelidis A et al Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features Cancer Res 2012 Oct 157220 530716","journal-title":"Cancer Res"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/modpathol.2015.99","article-title":"Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype","volume":"28","author":"Ribera-Cortada I Martinez D Amador V Royo C Navarro A Be\u00e0 S et al","year":"2015","unstructured":"11. Ribera-Cortada I Martinez D Amador V Royo C Navarro A Be\u00e0 S et al Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype Mod Pathol 2015 Nov2811 143547","journal-title":"Mod Pathol"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The Non-Hodgkin's Lymphoma Classification Project","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma","year":"1997","unstructured":"12. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma The Non-Hodgkin's Lymphoma Classification Project Blood 1997 Jun 18911 390918","journal-title":"Blood"},{"issue":"11","key":"ref13","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","article-title":"Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype","volume":"15","author":"Bernard M Gressin R Lefr\u00e0re F Dr\u00e9nou B Branger B Caulet-Maugendre S et al","year":"2001","unstructured":"13. Bernard M Gressin R Lefr\u00e0re F Dr\u00e9nou B Branger B Caulet-Maugendre S et al Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype Leukemia 2001 Nov1511 178591","journal-title":"Leukemia"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","article-title":"CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma","volume":"121","author":"Salaverria I Royo C Carvajal-Cuenca A Clot G Navarro A Valera A et al","year":"2013","unstructured":"14. Salaverria I Royo C Carvajal-Cuenca A Clot G Navarro A Valera A et al CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma Blood 2013 Feb 211218 1394402","journal-title":"Blood"},{"issue":"8","key":"ref15","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The mantle cell lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler CH Kolstad A Laurell A R\u00e4ty R Jerkeman M Eriksson M et al","year":"2010","unstructured":"15. Geisler CH Kolstad A Laurell A R\u00e4ty R Jerkeman M Eriksson M et al The mantle cell lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first line immunochemotherapy and autologous stem cell transplantation (ASCT) Blood 2010 Feb 251158 15303","journal-title":"Blood"},{"issue":"16","key":"ref16","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks K","year":"2018","unstructured":"16. Maddocks K Update on mantle cell lymphoma Blood 2018 Oct 1813216 16471656","journal-title":"Blood"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Out-come of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin P Chadburn A Christos P Weil K Furman RR Ruan J et al","year":"2009","unstructured":"17. Martin P Chadburn A Christos P Weil K Furman RR Ruan J et al Out-come of deferred initial therapy in mantle-cell lymphoma J Clin Oncol 2009 Mar 10278 120913","journal-title":"J Clin Oncol"},{"issue":"13","key":"ref18","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill S Thieblemont C Oberic L Moreau A Bouabdallah K Dartigeas C et al","year":"2017","unstructured":"18. Le Gouill S Thieblemont C Oberic L Moreau A Bouabdallah K Dartigeas C et al Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma N Engl J Med 2017 Sep 2837713 12501260","journal-title":"N Engl J Med"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma","volume":"173","author":"Armand P Redd R Bsat J Mayuram S Giardino A Fisher DC et al","year":"2016","unstructured":"19. Armand P Redd R Bsat J Mayuram S Giardino A Fisher DC et al A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma Br J Haematol 2016 Apr1731 8995","journal-title":"Br J Haematol"},{"issue":"10044","key":"ref20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine O Hoster E Walewski J Bosly A Stilgenbauer S Thieblemont C et al","year":"2016","unstructured":"20. Hermine O Hoster E Walewski J Bosly A Stilgenbauer S Thieblemont C et al Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network Lancet 2016 Aug 638810044 56575","journal-title":"Lancet"},{"issue":"9873","key":"ref21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel MJ Niederle N Maschmeyer G Banat GA von Gr\u00fcnhagen U Losem C et al","year":"2013","unstructured":"21. Rummel MJ Niederle N Maschmeyer G Banat GA von Gr\u00fcnhagen U Losem C et al Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Lancet 2013 Apr 63819873 120310","journal-title":"Lancet"},{"issue":"19","key":"ref22","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn IW van der Jagt R Kahl BS Wood P Hawkins TE Macdonald D et al","year":"2014","unstructured":"22. Flinn IW van der Jagt R Kahl BS Wood P Hawkins TE Macdonald D et al Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Blood 2014 May 812319 294452","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","article-title":"Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial) [abstract]","volume":"34","author":"Rummel MJ Knauf W Goerner M Soeling U Langeet E Hertenstein B et al","year":"2016","unstructured":"23. Rummel MJ Knauf W Goerner M Soeling U Langeet E Hertenstein B et al Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial) [abstract] J Clin Oncol 2016 34 7503","journal-title":"J Clin Oncol"},{"issue":"14","key":"ref24","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma","volume":"128","author":"Albertsson-Lindblad A Kolstad A Laurell A R\u00e4ty R Gr\u00f8nb\u00e6k K Sundberg J et al","year":"2016","unstructured":"24. Albertsson-Lindblad A Kolstad A Laurell A R\u00e4ty R Gr\u00f8nb\u00e6k K Sundberg J et al Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma Blood 2016 Oct 612814 18141820","journal-title":"Blood"},{"key":"ref25","first-page":"154","article-title":"Initial treatment with lenalidomide plus rituximab for mantle cell lymphoma: 5-year follow-up and correlative analysis from a multi-center phase II study","volume":"130","author":"Ruan J Martin P Christos PJ Cerchietti L Shah BD Schuster SJ et al","year":"2017","unstructured":"25. Ruan J Martin P Christos PJ Cerchietti L Shah BD Schuster SJ et al Initial treatment with lenalidomide plus rituximab for mantle cell lymphoma: 5-year follow-up and correlative analysis from a multi-center phase II study Blood 2017 Dec 8130 154","journal-title":"Blood"},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang ML Blum KA Martin P Goy A Auer R Kahl BS et al","year":"2015","unstructured":"26. Wang ML Blum KA Martin P Goy A Auer R Kahl BS et al Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results Blood 2015 Aug 61266 73945","journal-title":"Blood"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang ML Rule S Martin P Goy A Auer R Kahl BS et al","year":"2013","unstructured":"27. Wang ML Rule S Martin P Goy A Auer R Kahl BS et al Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma N Engl J Med 2013 Aug 83696 50716","journal-title":"N Engl J Med"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling M Lenz G Hoster E Van Hoof A Gisselbrecht C Schmits R et al","year":"2005","unstructured":"28. Dreyling M Lenz G Hoster E Van Hoof A Gisselbrecht C Schmits R et al Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network Blood 2005 Apr 11057 267784","journal-title":"Blood"},{"issue":"8","key":"ref29","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids MS Roberts AW Seymour JF Pagel JM Kahl BS Wierda WG et al","year":"2017","unstructured":"29. Davids MS Roberts AW Seymour JF Pagel JM Kahl BS Wierda WG et al Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma J Clin Oncol 2017 Mar 10358 826833","journal-title":"J Clin Oncol"},{"issue":"21","key":"ref30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V124.21.509.509","article-title":"Synergistic cytotoxicity of ibrutinib and the BCL2 antagonist, ABT-199(GDC-0199) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL): molecular analysis reveals mechanisms of target interactions","volume":"124","author":"Portell CA Axelrod M Brett LK Gordon VL Capaldo B Xing JC et al","year":"2014","unstructured":"30. Portell CA Axelrod M Brett LK Gordon VL Capaldo B Xing JC et al Synergistic cytotoxicity of ibrutinib and the BCL2 antagonist, ABT-199(GDC-0199) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL): molecular analysis reveals mechanisms of target interactions Blood 2014 Dec 612421 509","journal-title":"Blood"},{"issue":"16","key":"ref31","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer JN Somerville RPT Lu T Shi V Bot A Rossi J et al","year":"2017","unstructured":"31. Kochenderfer JN Somerville RPT Lu T Shi V Bot A Rossi J et al Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels J Clin Oncol 2017 Jun 13516 18031813","journal-title":"J Clin Oncol"}],"container-title":["The Pan African Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.panafrican-med-journal.com\/\/content\/article\/47\/111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T03:08:15Z","timestamp":1717211295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.panafrican-med-journal.com\/\/content\/article\/47\/111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":31,"URL":"https:\/\/doi.org\/10.11604\/pamj.2024.47.111.40405","relation":{},"ISSN":["1937-8688"],"issn-type":[{"value":"1937-8688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}